You need the Flash Player version 8.0.0.0 or higher and a JavaScript enabled browser to view this content

Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: BNO
News: Latest news
Web Site: Bionomics Limited
Other Articles: 28-06-201021-06-201007-06-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Saturday September 04, 06:00Serving up support at Babcock

Support services have been among the worst performing sectors over the past month as revenue fears from the government’s austerity measures weigh heavily on the sector.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Friday September 03, 11:40 Goldcorp snatches Andean Resources in $3.6bn deal, trumping Eldorado`s earlier bid

Both companies are vying for Andean`s Cerro Negro gold project, which is an advanced-stage, high-grade vein system, comprising 215 square kilometers. It currently has indicated resources of 2.54 million ounces of gold and 23.56 million ounces of silver, while inferred resources total 523,000 ounces of gold and 3.12 million ounces of silver.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 10:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
Bionomics Limited

Bionomics Limited

Bionomics (ASX: BNO) is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system (CNS). Through application of its proprietary technology platforms, MultiCore®, Angene® and ionX®.

The company has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy. The company has a strong out-license record in conjunction with its in-house development program which has seen two highly promising drugs enter clinical trials in the past two years.

CLICK HERE FOR FULL ANALYSIS OF BIONOMICS LIMITED
Monday, June 28, 2010

Edison Investment Research maintains valuation of Bionomics

by Proactive Investors company news image

Code BNO/BMICY
Listing ASX/NASDAQ
Sector Biotech
Shares in issue 318.1m
Debt/Equity (%) N/A
NAV per share (c) 8.2
Net cash (A$m) 10.1

Bionomics is selecting doses for two planned Phase Ib studies of its anxiety compound BNC210, which are due to begin enrolment shortly and are expected to report results in Q1 next year. The studies will be conducted in healthy volunteers, but will provide some efficacy data through use of an induced-anxiety model and measurement of cortisol.

Meanwhile, Phase II studies of the VDA BNC105 in renal carcinoma and mesothelioma are both recruiting well and should provide some interim data in late 2010 and early 2011 respectively. These data are likely to be important in Bionomics’ efforts to establish a corporate partnership.

Two Phase Ib studies of BNC210 planned

Bionomics is finalising plans to undertake two Phase Ib trials of BNC210. The first of the new trials will evaluate BNC210 effects when anxiety is induced in healthy subjects and the second trial will evaluate BNC210 effects on the brain using EEG measurements. Both studies will measure cortisol and other biomarkers of anxiety.

ASCO presentation should raise BNC105 profile

Bionomics continues to raise the profile of BNC105, capitalising on the unexpected boost to its competitive position in the VDA class with the failure of the ATTRACT-1 study of Novartis/Antisoma’s ASA404. Data from Phase I studies of BNC105 were presented at ASCO.

Cash: Funded for two years

Forecast cash of A$13m (net cash of A$10.1m) as at 30 June 2010 is sufficient to fund the company for the next two years and support the trial programmes for BNC105 and BNC210, providing a window for Bionomics to partner one or both products.

Valuation: Valuation of A$175m based on risked NPV

"We maintain our A$175m valuation of Bionomics based on a risk-adjusted netpresent value of the two key programmes. This is derived from our assessment of the potential economic reward and timelines associated with the successful development of BNC105 and BNC210," the Edison Investment Research reported.

AddThis Feed Button
Register here to be notified of Proactiveinvestors One2One Forums.

Other Bionomics Limited articles


Other Bionomics Limited news

More news ►

Investors interested in Bionomics Limited recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.